Literature DB >> 6360436

Marked reduction of DNA antibody production and glomerulopathy in thymulin (FTS-Zn) or cyclosporin A treated (NZB X NZW) F1 mice.

D Israel-Biet, L H Noel, M A Bach, M Dardenne, J F Bach.   

Abstract

In this study we have evaluated the action of two compounds, cyclosporin A (Cy A) and thymulin (FTS-Zn) in old (NZB X NZW) F1 male mice which develop severe autoimmune disease. Compared with control mice, thymulin and Cy A treated mice already showed by 2 weeks a dramatic diminution of their anti-DNA antibody level which remained low throughout the treatment period and persisted for 7 weeks afterwards. Renal specimens were studied by direct immunofluorescence in Cy A and thymulin treated mice. Glomerular deposits were decreased compared with control mice; these differences were particularly clearcut for IgG1 and IgG2 deposits. Finally, thymulin (FTS-Zn) and Cy A appeared to induce the same improvement of DNA titres and glomerulopathy in (NZB X BW) F1 mice.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6360436      PMCID： PMC1535908     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  9 in total

1.  Effect of altered lymphocyte function on immunologic disorders in NZB/NZW mice. III. Acceleration of disease by thymosin.

Authors:  J Mehta; L Knotts; C Craig; S Burkholder; C Miller; B Hahn
Journal:  Arthritis Rheum       Date:  1978-03

2.  Mode of action of cyclosporin A: a new immunosuppressive agent.

Authors:  D J White; R Y Calne; A Plumb
Journal:  Transplant Proc       Date:  1979-03       Impact factor: 1.066

3.  Studies on thymus products. IV. Absence of serum 'thymic activity' in adult NZB and (NZB x NZW) F1 mice.

Authors:  J F Bach; M Dardenne; J C Salomon
Journal:  Clin Exp Immunol       Date:  1973-06       Impact factor: 4.330

4.  [Role of zinc and other metals in the biological activity of the serum thymic factor (thymulin)].

Authors:  M Dardenne; J M Pleau; P Lefrancier; J F Bach
Journal:  C R Seances Acad Sci III       Date:  1981-03-30

5.  Age-dependent loss in New Zealand mice of morphological and functional characteristics of thymic epithelial cells.

Authors:  M E Gershwin; R M Ikeda; W L Kruse; F Wilson; M Shifrine; W Spangler
Journal:  J Immunol       Date:  1978-03       Impact factor: 5.422

6.  Effects of the new anti-lymphocytic peptide cyclosporin A in animals.

Authors:  J F Borel; C Feurer; C Magnée; H Stähelin
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

7.  Cyclosporin A in patients receiving renal allografts from cadaver donors.

Authors:  R Y Calne; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; B D Pentlow; K Rolles
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

8.  Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation.

Authors:  R L Powles; H M Clink; D Spence; G Morgenstern; J G Watson; P J Selby; M Woods; A Barrett; B Jameson; J Sloane; S D Lawler; H E Kay; D Lawson; T J McElwain; P Alexander
Journal:  Lancet       Date:  1980-02-16       Impact factor: 79.321

9.  Studies on the immunosuppressive properties of cyclosporin a in rats receiving renal allografts.

Authors:  W P Homan; J W Fabre; K A Williams; P R Millard; P J Morris
Journal:  Transplantation       Date:  1980-05       Impact factor: 4.939
  9 in total
  12 in total

1.  Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: II. Reduction of glomerulonephritis.

Authors:  H C Gunn; B Ryffel
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

2.  Effect of cyclosporin A on autoimmune tubulointerstitial nephritis in the brown Norway rat.

Authors:  A Giménez; F Leyva-Cobián; C Fierro; M Río; T Bricio; F Mampaso
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

3.  Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials.

Authors:  B Amor; M Dougados; C Mery; M Dardenne; J F Bach
Journal:  Ann Rheum Dis       Date:  1987-07       Impact factor: 19.103

4.  The effects of CP 17193, an immunosuppressive pyrazaloquinoline, on the development of spontaneous lupus disease in NZBW F1 hybrid mice.

Authors:  R V Bundick; R P Eady
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

Review 5.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

6.  Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice.

Authors:  S Ikehara; K Shimamura; T Aoyama; S Fujii; Y Hamashima
Journal:  Immunology       Date:  1985-08       Impact factor: 7.397

Review 7.  Lupus nephritis in childhood and adolescence.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

8.  Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: I. Reduction of autoantibodies.

Authors:  H C Gunn
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

9.  Suppression of autoimmune disease in NZB/W F1 mice by treatment with the novel immunomodulator BTS 63155.

Authors:  P Appleby; G Telford; G B Naylor
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

10.  Cyclosporin A and anti-glomerular basement membrane antibody glomerulonephritis in rats.

Authors:  A Wood; D Adu; R J Birtwistle; D B Brewer; J Michael
Journal:  Br J Exp Pathol       Date:  1988-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.